Evidence map›Paper›PMID 37887031›Full record

ArticleBiology2023

Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies.

Diego Montoya-Durango, Mary Nancy Walter, Walter Rodriguez, Yali Wang, Julia H Chariker, Eric C Rouchka, Claudio Maldonado, Shirish Barve, Craig J McClain, Leila Gobejishvili

Open access · goldAbstract read
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Lipid Droplet Dynamics in Alcoholic Steatohepatitis.The American journal of pathology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Diego Montoya-DurangoDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
Mary Nancy WalterDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.ORCID 0000-0003-2246-8504
Walter RodriguezDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
Yali WangDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
Julia H CharikerDepartment of Neuroscience Training, University of Louisville, Louisville, KY 40290, USA.
Eric C RouchkaKY INBRE Bioinformatics Core, University of Louisville, Louisville, KY 40290, USA.ORCID 0000-0003-3487-6572
Claudio MaldonadoDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
Shirish BarveDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
Craig J McClainDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY 40290, USA.ORCID 0000-0002-7219-8939
Leila GobejishviliDepartment of Physiology, School of Medicine, University of Louisville, Louisville, KY 40290, USA.
University of Louisville · US

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI GHARE, SMITA S · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI SHIRISH S BARVE · 2016 to 2026
$17.9M
Clinical Resources for Alcoholic Hepatitis InvestigationsR24AA025017 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI ZHAOLI SUN · 2016 to 2026
$6.6M
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver diseaseR01AA029798 · NIAAA · UNIVERSITY OF LOUISVILLE · PI GOBEJISHVILI, LEILA · 2021 to 2025
$2.2M
Novel Drug Carrier System for the Treatment of Alcoholic Liver DiseaseR44AA021331 · NIAAA · ENDOPROTECH, INC. · PI BAUER, PHILIP, GOBEJISHVILI, LEILA · 2015 to 2016
$1.4M
Lipid metabolites can both potentiate and treat alcoholic hepatitisU01AA026936 · NIAAA · UNIVERSITY OF LOUISVILLE · PI JOSHI-BARVE, SWATI, MCCLAIN, CRAIG J. · 2018 to 2022
$1.2M
NIAAA NIH HHS P50 AA011999NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA029798NIAAA NIH HHS R24 AA025017NIAAA NIH HHS R44 AA021331NIAAA NIH HHS U01 AA026936NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P20 GM113226
6 · The paper itself

Abstract

backgroundCyclic nucleotides are second messengers, which play significant roles in numerous biological processes. Previous work has shown that cAMP and cGMP signaling regulates various pathways in liver cells, including Kupffer cells, hepatocytes, hepatic stellate cells, and cellular components of hepatic sinusoids. Importantly, it has been shown that cAMP levels and enzymes involved in cAMP homeostasis are affected by alcohol. Although the role of cyclic nucleotide signaling is strongly implicated in several pathological pathways in liver diseases, studies describing the changes in genes regulating cyclic nucleotide metabolism in ALD are lacking.

methodsMale C57B/6 mice were used in an intragastric model of alcohol-associated steatohepatitis (ASH). Liver injury, inflammation, and fibrogenesis were evaluated by measuring plasma levels of injury markers, liver tissue cytokines, and gene expression analyses. Liver transcriptome analysis was performed to examine the effects of alcohol on regulators of cyclic AMP and GMP levels and signaling. cAMP and cGMP levels were measured in mouse livers as well as in livers from healthy human donors and patients with alcohol-associated hepatitis (AH).

resultsOur results show significant changes in several phosphodiesterases (PDEs) with specificity to degrade cAMP (Pde4a, Pde4d, and Pde8a) and cGMP (Pde5a, Pde6d, and Pde9a), as well as dual-specificity PDEs (Pde1a and Pde10a) in ASH mouse livers. Adenylyl cyclases (ACs) 7 and 9, which are responsible for cAMP generation, were also affected by alcohol. Importantly, adenosine receptor 1, which has been implicated in the pathogenesis of liver diseases, was significantly increased by alcohol. Adrenoceptors 1 and 3 (Adrb), which couple with stimulatory G protein to regulate cAMP and cGMP signaling, were significantly decreased. Additionally, beta arrestin 2, which interacts with cAMP-specific PDE4D to desensitize G-protein-coupled receptor to generate cAMP, was significantly increased by alcohol. Notably, we observed that cAMP levels are much higher than cGMP levels in the livers of humans and mice; however, alcohol affected them differently. Specifically, cGMP levels were higher in patients with AH and ASH mice livers compared with controls. As expected, these changes in liver cyclic nucleotide signaling were associated with increased inflammation, steatosis, apoptosis, and fibrogenesis.

conclusionsThese data strongly implicate dysregulated cAMP and cGMP signaling in the pathogenesis of ASH. Future studies to identify changes in these regulators in a cell-specific manner could lead to the development of novel targeted therapies for ASH.

Indexed as

alcohol-associated steatohepatitiscAMPcGMPliverphosphodiesterases

Identifiers

PMID37887031
PMCPMC10604143
OpenAlexW4387500659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.